Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment
Source: Streetwise Reports  (11/20/21)
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome. More >

This New Cryptographic Technology Seals Data, Repels Tampering By Hackers & Ransomware Attackers
Source: Streetwise Reports  (11/19/21)
Streetwise spoke with Raymond Pomroy, CEO of SoLVBL, and investor and advisor to SoLVBL, Rahim Allani, to learn more about the company's new security technology "Q by SoLVBL." More >

Step-Out Drilling Results Offer Explorer Strong Basis for Resource Expansion at IBW Property
Source: Streetwise Reports  (11/19/21)
Emerita Resources Corp. recently announced encouraging step-out drilling results from its Iberia Belt West property in Spain. The firm is now activating three new diamond drilling rigs to accelerate exploration work. Clarus Securities Inc. commented in a research note that it is maintaining its "Speculative Buy" rating for the company and due to higher commodity market prices is raising its price target for the firm's shares to CA$5.00. More >

Where Is U.S. Global Investors Investing Now?
Source: Streetwise Reports  (11/18/21)
U.S. Global Investors, which has historically focused on resource and precious metals investing prior to launching its global airlines ETF in 2015, is now branching out to a new sector. Streetwise Reports speaks to Frank Holmes, CEO and Chief Investment Officer, who discusses the path ahead for gold as well as the new investment area for the firm that he believes global economic imbalances have primed for profits. More >

This Microcap With Gold-Silver Assets Is a Buy
Source: Streetwise Reports  (11/18/21)
Microcap gold stocks offer investors exposure to gold’s upside in an inflationary environment while providing a bit of fun as your position rides the waves of investor confidence. An expert analyst has made Inomin Mines Inc. his latest pick. As long as you can stomach the risk, the ride could pay off with much more than what you put into it. More >

Explorer Expands Mineralized Footprint at Idaho Project, Plans to Drill Through Winter
Source: Streetwise Reports  (11/18/21)
"Today's results from Liberty Gold show the growth potential inherent in the providence of the gold mineralized system on the project area," noted a Haywood Securities report. More >

RNA Silencing Platform Firm Receives US$3.3 Billion Buyout Offer From Novo Nordisk
Source: Streetwise Reports  (11/18/21)
Shares of Dicerna Pharmaceuticals Inc. traded 78% higher after the company reported it entered into a definitive agreement to be acquired by Novo Nordisk A/S of Denmark for $38.25 per share in cash. More >

B.C.-Based Royalty Firm to Acquire First Precious Metal Stream
Source: Streetwise Reports  (11/17/21)
"This first stream represents an important milestone in terms of opportunities originated by Nomad Royalty Company since inception," noted a BMO Capital Markets report. More >

Miner Delivers a 'Record Quarter and Still Getting Better,' Analyst Says
  (11/17/21)
"Given this actual and expected strong balance sheet, we expect Teck Resources could announce a one-time capital return to shareholders with its February earnings and guidance release," noted a BMO Capital Markets report. More >

Daybreak in the Land of Precious Metals
Source: Michael Ballanger for Streetwise Reports  (11/17/21)
Michael Ballanger dissects last week's price gains in gold and silver. More >

West Wits About to Begin Gold Production
Source: Bob Moriarty for Streetwise Reports  (11/17/21)
According to Bob Moriarty of 321Gold, West Wits Mining Limited is worth a buy ... if you can get your hands on it that is. More >

Novavax Submits Request to EMA for Conditional Marketing Authorization for COVID-19 Vaccine
Source: Streetwise Reports  (11/17/21)
Shares of Novavax Inc. traded 10% higher after the firm confirmed that the European Medicines Agency is now reviewing its COVID-19 vaccine filing for conditional marketing authorization. The firm advised that an opinion from the agency is expected within a few weeks. More >

Analyst: Maiden Drilling of New Target in White Gold District Yields 'Significant' Results
Source: Streetwise Reports  (11/17/21)
White Gold encountered two types of mineralization in a newly identified breccia unit at Betty Ford, a Stifel report noted. More >

Why Buy This Stock While It's Still Very Cheap, Analyst Explains
Source: Ron Struthers for Streetwise Reports  (11/17/21)
Expert analyst Ron Struthers — founder and editor of Struthers' Resource Stock Report — breaks it all down, in a November 15 report, about what makes Inomin Mines Inc. his latest pick. More >

For B.C. Project, Top Pick Gold Company Eyes Integrated Mine Plan Likely to Attract Partner
Source: Streetwise Reports  (11/16/21)
"A joint venture partnership would arguably be the single largest and most important derisking event in Seabridge Gold's history and as such, the upside ahead of a partnering event is potentially massive," noted a Cantor Fitzgerald report. More >

Market Overreacts to Silver Producer's Setback
Source: Adrian Day for Streetwise Reports  (11/16/21)
Adrian Day of Global Analyst delves into what the denial of the renewal of a mining permit in Mexico means for Fortuna Silver. More >

Biotech Co.'s Shares Gain 32% After Posting Meaningful Renal Response Rates in Ph. 2 Lupus Study
Source: Streetwise Reports  (11/16/21)
Shares of Kezar Life Sciences Inc. rose to a new 52-week high after the company reported promising interim results from its Phase 2 trial of KZR-616 in patients with lupus nephritis. More >

Oil & Gas Firm's Cash Flow Expected to Remain Strong Through 2022, Analyst Says
Source: Streetwise Reports  (11/15/21)
"Higher commodity prices are providing Gran Tierra Energy with additional financial flexibility to service debt and to fund growth in 2022," noted a Research Capital Corporation report. More >

EyePoint Pharma Reduces Wet AMD Treatment Burden by 79% after 6 Mo.'s in Phase 1 Trial
Source: Streetwise Reports  (11/15/21)
Shares of EyePoint Pharmaceuticals Inc. reached a new 52-week intraday high after the company reported positive data from its Phase 1 DAVIO study of EYP-1901 in Wet AMD and announced plans to move forward to additional Phase 2 clinical trials in 2022. More >

Trial of Psilocybin Therapeutic in Treatment Resistant Depression Yields Positive Topline Results
Source: Streetwise Reports  (11/14/21)
"We believe this data begins to form the basis of an approvable program for Compass Pathways' COMP360" in this indication, noted a BTIG report. More >

Liquid Avatar Leverages Blockchain Tech for Age Verification & NFTs
Source: Streetwise Reports  (11/13/21)
In a recent conversation with Streetwise Reports, David Lucatch, CEO and president of Liquid Avatar, talked about the company's multifaceted approach to bringing blockchain technology to people's everyday experiences and transactions. More >

This Tech Trailblazer Is Recycling Platinum & Palladium From Catalytic Converters
Source: Streetwise Reports  (11/13/21)
Small tech company Mineworx has partnered with a Tennessee recycling company to extract platinum and palladium from diesel catalytic converters in a ground-breaking method that bypasses smelting, a major polluter. More >

Junior Miner Monetizes Non-Core Assets
Source: Streetwise Reports  (11/13/21)
Quebec Precious Metals CEO Normand Champigny discusses how his company's sale of non-core assets is funding its gold exploration programs in the James Bay region of Quebec. More >

Contakt World Technologies Partnership Will Help Satisfy Demand for Vaccine Passport Technology
Source: Streetwise Reports  (11/12/21)
Contakt World plans to build a diversified health technology SaaS platform and address inequity of health access through technology. More >

Advanced Medical Genetics Co. Notches 66% YoY Increase in Q3 Revenue
Source: Streetwise Reports  (11/12/21)
Invitae Corp. reported Q3/21 financial results that highlighted an 89% YoY increase in billable volume to 296,000 tests. Ladenburg Thalmann & Co. Inc. stated in a research note that it has a "Buy" rating for the company with a $55.00/share price target. More >